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Abstract
Background: Patients with the lupus anticoagulant (LA) are at an increased risk of thrombotic events, which in turn
increase the risk of death. Understanding the determinants of thrombotic risk in patients with LA may pave the way
towards targeted thromboprophylaxis. In the Vienna Lupus Anticoagulant and Thrombosis Study (LATS), we
systematically evaluate risk factors for thrombotic events in patients with LA.
Methods: We followed 150 patients (mean age: 41.3 years, female gender: n = 122 (81.3%), history of thrombosis or
pregnancy complications: n = 111 (74.0%)), who tested repeatedly positive for LA until development of thrombosis,
death, or censoring. The primary endpoint was a composite of arterial or venous thrombotic events (TEs).
Results: During a median follow-up of 9.5 years (range: 12 days–13.6 years) and 1076 person-years, 32 TEs occurred
(arterial: n = 16, venous: n = 16; cumulative 10-year TE incidence: 24.3%). A prolonged lupus-sensitive activated
partial thromboplastin time (aPTT-LA) (adjusted subdistribution hazard ratio (SHR) = 2.31, 95% CI: 1.07–-5.02),
diabetes (adjusted SHR = 4.39, 95% CI: 1.42–13.57), and active smoking (adjusted SHR = 2.31, 95% CI: 1.14–5.02)
emerged as independent risk factors of both arterial and venous thrombotic risk. A risk model that includes a
prolonged lupus-sensitive aPTT, smoking, and diabetes enabled stratification of LA patients into subgroups with a
low, intermediate, and high risk of thrombosis (5-year TE risk of 9.7% (n = 77), 30.9% (n = 51), and 56.8% (n = 22).
Conclusions: Long-term thrombotic risk in patients with LA is clustered within subjects harboring typical
cardiovascular risk factors in addition to a prolonged lupus-sensitive aPTT, whereas patients with none of these risk
factors represent a large subgroup with a low risk of thrombosis.
Keywords: Lupus anticoagulant, Antiphospholipid antibody syndrome, Thrombotic risk, Risk stratification model,
Second hit, diabetes, aPTT, Smoking, Cardiovascular risk factors
Background
Autoantibodies directed against phospholipid-binding
plasma proteins (also known as antiphospholipid (aPL)
antibodies), detected through coagulation assays such as
the lupus anticoagulant (LA) and through immunoassays
such as anticardiolipin (aCL) or anti-β2-glycoprotein I
(aβ2-GPI), confer an increased risk of arterial and
venous thrombosis [1]. In vitro, the interference by these
autoantibodies with the clotting cascade is reflected in
the prolongation of phospholipid-dependent clotting
assays, such as the activated partial thromboplastin time
(aPTT) [2]. Conversely, in vivo, a complex and still enig-
matic interplay of these antibodies with coagulation
factors, platelets, and the vessel wall induces a hyperco-
agulable state that can lead to overt thrombosis and/or
adverse pregnancy outcomes [3]. The clinical manifest-
ation of these events in a patient who is persistently
positive for one or more of these autoantibodies defines
the antiphospholipid syndrome (APS) [4].
Cervera et al. and our group have recently demon-
strated that the occurrence of thrombosis in patients
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with LA is associated with an excessive increase in the
risk of death, which in turn leads to a significantly im-
paired relative survival of these patients in comparison
to an age- and sex-matched reference population [5, 6].
While anticoagulation may reduce the risk of throm-
bosis, it is currently unclear which patient groups are at
the highest risk for the development of thrombotic com-
plications [3]. Further, a considerable proportion of
patients with LA will not develop thrombosis despite the
presence of aPL-associated autoantibodies at high titers
[7]. The large uncertainty around the potential determi-
nants of thrombotic risk in LA-positive patients is
further aggravated by inconsistent study results on the
role of aPL-associated autoantibodies for thrombotic risk
stratification, and the rarity of adequately powered pro-
spective studies [1, 7–16]. A robust risk stratification
tool for long-term thrombotic outcomes in patients with
LA therefore represents an unmet clinical need [3].
Here, we report results from a prospective observa-
tional cohort study in which we studied the course of
disease in patients with LA over time. By systematically
analyzing risk factors for the occurrence of thrombosis,
we develop a rational basis for thrombotic risk stratifica-
tion in patients with LA.
Methods
Study design and endpoint
The Vienna Lupus Anticoagulant and Thrombosis Study
(LATS) is an ongoing, single-center, biobank-based, pro-
spective observational cohort study enrolling adult
patients who repeatedly test positive for LA (two posi-
tive tests at least 12 weeks apart) with or without a
history of thrombosis or pregnancy complications [5].
The primary endpoint of the study is a composite of
symptomatic, objectively confirmed arterial and/or ven-
ous thrombosis. Comprehensive details about the design
of this study have been reported previously [5] and can
be found in Additional file 1: paragraph 1.
Determination of LA and LA-associated autoantibodies
Blood sample preparation procedures are reported in
Additional file 2: paragraph 2. LA was diagnosed accord-
ing to Scientific and Standardization Committee (SSC)/
International Society on Thrombosis and Hemostasis
(ISTH) recommendations [17, 18]. A lupus-sensitive
activated partial thromboplastin time (PTT-LA,
Diagnostica Stago, Asniere-sur-Seine, France) and a di-
luted Russell’s viper venom time (dRVVT) were used as
screening tests. For screening during therapy with vita-
min K antagonists (VKAs), only the aPTT was used.
Confirmatory tests were performed following the meth-
odology of Wenzel et al. in the case of prolongation of
one or both screening tests [19]. As confirmatory assays
the StaClot LA (Diagnostica Stago, Asniere-sur-Seine,
France) and the dRVVT-LA Confirm (Life Diagnostics,
Clarkston, GA, USA) were used. In case of a not defin-
itely positive confirmatory test during the follow-up
period, LA was still regarded as positive if the Rosner
Index, calculated as 100 × (clotting times of the 1:1 mix-
ture - normal plasma)/patient’s plasma, was higher than
15 [20]. Commercially available indirect solid-phase
enzyme immunoassays were used to determine IgG and
IgM antibodies against cardiolipin (aCL) and β2-GPI.
Between 2001 and September 2005, the Varelisa Cardio-
lipin test (Pharmacia (Phadia AB), Uppsala, Sweden) was
performed semi-automatically with a Tecan Genesis
liquid handling system (Tecan Group Ltd., Maennedorf,
Switzerland). From October 2005 the Orgentec Cardioli-
pin and, from October 2006, the Orgentec β2-GPI tests
(both from Orgentec, Mainz, Germany) were performed
on a fully automated BEP2000 Advance System (Siemens
Healthcare Diagnostics, Marburg, Germany). All assays
were used following the manufacturers’ instructions.
Positivity for aCL IgG and aCL IgM was defined as
results >40 IgG phospholipid units (GPL)/IgM phospho-
lipid units (MPL) U/mL for both the Varelisa Cardiolipin
and the Orgentec Cardiolipin tests according to the
revised Sapporo criteria [4]. Two further aCL cut-offs
were analyzed as a sensitivity analysis (see the legends of
Tables 1 and 3). For aβ2-GPI IgG and IgM (Orgentec as-
says), results >8U/mL were regarded as positive (corre-
sponding to the 99th percentile of healthy controls).
IgM- and IgG-isotype antibodies against prothrombin
and protein Z were measured using commercially avail-
able enzyme-linked immunosorbent assay kits from the
Zymutest product line (Hyphen Biomed, Neuville-sur-
Oise, France). The annexin A5 resistance ratio (A5R)
was measured as previously described, expressed as the
ratio of in vitro coagulation times with and without
annexin A5 [21]. IgG-isotype autoantibodies against
domain I of β2-GPI were measured with a chemilumin-
escent immunoassay (QUANTA Flash/Bioflash, Inova
Diagnostics, San Diego, CA, USA) [9].
Statistical methods
The statistical analysis is described in detail in
Additional file 3: paragraph 3. Briefly, median follow-up
time was estimated with the reverse Kaplan-Meier esti-
mator [22]. Patients who became LA negative during
follow-up (n = 11) were censored at the date of the first
negative LA test. The cumulative incidence of the pri-
mary endpoint was calculated with cumulative incidence
estimators according to Marubini and Valsecchi, treating
death from any cause as a competing risk [23]. Differ-
ences in thrombosis incidence functions between two or
more groups were investigated using Gray’s test [24].
The association between potential risk factors and the cu-
mulative incidence of thrombosis was modeled with uni-
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and multivariable proportional subdistribution hazards
models according to Fine and Gray [25]. To increase external
generalizability, modeling was also performed using an aPTT
ratio, which was defined as the ratio of the lupus-sensitive
aPTT of a patient divided by the mean of the lupus-sensitive
aPTT in healthy controls at our department (mean = 34.09 s,
SD = 0.476). A backward selection algorithm (p for exclusion
= 0.10) including all four univariable predictors of throm-
botic risk with p < 0.10 (lupus-sensitive aPTT ratio (dichoto-
mized into a binary variable at the 75th percentile of the
distribution (117.5 s)), diabetes, smoking, and aCL IgM anti-
bodies) was applied to construct a multivariable model for
the prediction of thrombotic risk [26]. The algorithm se-
lected the three variables diabetes, smoking, and a prolonged
lupus-sensitive aPTT, and we constructed an empirical risk
stratification rule by assigning 2 points for diabetes, and 1
point for each of the risk factors smoking and a prolonged
lupus-sensitive aPTT. These points were chosen because
they were consistent with an additive effect of the underlying
predictor variables on the log hazard scale (further details
are reported in Additional file 3: paragraph 3) [27]. Discrim-
ination of the proposed stratification rule was assessed using
Harrell’s C statistic, and calibration was explored by compar-
ing the observed and predicted 5- and 10-year cumulative in-
cidences of thrombosis [28]. Finally, in a sensitivity analysis,
we assessed the separate association between the three risk
stratification variables and the prospective risk of arterial and
venous thrombosis (see Additional file 4: Table S1).
Results
Analysis at baseline
One hundred and fifty patients were included in the ana-
lysis. Patients were predominantly female, and 74.2%
had an established diagnosis of APS (Table 1). All pa-
tients were positive for LA, and 67 (44.7%), 105 (71.0%),
and 64 (43.2%) patients also had above-cut-off antibody
levels against cardiolipin (aCL), β2-GPI (aβ2-GPI), or
both (“triple positivity”). IgM- and IgG-isotype aCL and
aβ2-GPI antibodies were moderately strongly correlated
with each other. Some correlations were also observed
between elevated levels of these antibodies and (1)
higher levels of antibodies against prothrombin and
protein Z, (2) a lower annexin A5 anticoagulant ratio,
and (3) higher levels of IgG-isotype antibodies against
domain I of β2-GPI (Additional file 5: Table S2). A
long lupus-sensitive aPTT was significantly correlated
with a higher level of IgG-isotype antibodies against
domain I of β2-GPI (rho = 0.40, p < 0.0001) and a
lower prothrombin time (given as percent of normal,
rho = –0.27, p = 0.0007). The average levels of the
lupus-sensitive aPTT and fibrinogen were slightly but
non-statistically significantly elevated in VKA users
(Additional file 6: Table S3).
Analysis of anamnestic risk of thrombotic events (TEs)
and pregnancy complications
Ninety-eight patients (65.3%) had a history of thrombotic
events (TEs) before study inclusion (arterial: n =21, ven-
ous: n = 84, both: n = 7). Patients with a history of TE were
significantly younger than patients without a history of TE
and had a much higher probability of being on oral antic-
oagulation with VKA (odds ratio (OR) = 56.7, 95% CI:
12.9–248.2, p < 0.0001, Table 1). The median levels of
IgG-isotype antibodies against aCL and β2-GPI (Table 1)
and the odds of being “triple positive” were also signifi-
cantly higher in patients with prior TE (OR = 2.5, 95% CI:
1.2–5.1, p = 0.01). In patients with a prior history of TE,
we observed a significantly higher average antibody level
against domain I of β2-GPI and a significantly lower
annexin A5 anticoagulant ratio. LA-related antibodies
against prothrombin and/or protein Z did not appear to
consistently differ according to anamnestic thrombosis
status. Forty (42.6%) of the 94 female patients who had at
least one documented pregnancy had at least one preg-
nancy complication according to Sapporo criteria. These
40 women had significantly higher levels of IgG-isotype
aCL, aβ2-GPI, and domain 1-β2-GPI antibodies and were
also more likely to be “triple positive” (Additional file 7:
Table S4). Other parameters did not appear to differ be-
tween women with and without pregnancy complications.
Analysis of prospective risk of thrombosis
During a median follow-up of 9.5 years (range: 12 days–
13.6 years) and 1076 patient years, 32 patients developed
TE (arterial: n = 16, venous: n = 16). The most frequent
type of events were lower extremity deep vein throm-
bosis (n = 6) and pulmonary embolism (n = 6) in the ven-
ous vasculature, and cerebrovascular incidents (n = 9)
and myocardial infarction (n = 5) in the arterial vascula-
ture. Twenty-one of the 32 events occurred in patients
with a prior history of thrombosis (“recurrent throm-
bosis”), and 11 events occurred in LA-positive patients
without a prior history of thrombosis. Data on anti-
thrombotic therapy at the time of thrombosis were avail-
able for 31 out of 32 patients (Table 2). Twenty-three
(74.2%) of these 31 events occurred while patients were
receiving antithrombotic therapy (Table 2). In detail, 14
(45.2%), 4 (12.9%), and 7 (22.6%) of these patients were
receiving VKA, low molecular weight heparin, and/or
low dose aspirin at the time of thrombosis, respectively.
Among the 14 patients receiving VKA, the international
normalized ratio (INR) was insufficient (i.e., <2) in 6
patients, within therapeutic range in 5 patients, and
unknown in 3 patients. The cumulative 1-, 5-, 10-, and
15-year incidences of TE accounting for competing mor-
tality were 4.0% (95% CI: 1.7–8.1), 13.3% (95% CI: 8.3–
19.4), 24.3% (95% CI: 17.0–32.5), and 27.6% (95% CI:
19.3–36.6), respectively (Additional file 8: Figure S1).
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With 12 patients having died during follow-up without
developing TE, death was clearly present as a competing
risk in this population. Of the 32 patients who developed
thrombosis during follow-up, 2 patients developed a fur-
ther TE (1x venous thrombotic event (VTE) after VTE,
1x myocardial infarction after cerebrovascular insult).
In a univariable competing risk analysis, diabetes (sub-
distribution hazard ratio (SHR) = 5.18, 95% CI: 1.87–
14.31, p = 0.002), active smoking (SHR = 2.11, 95% CI:
1.06–4.20, p = 0.034), and a prolonged lupus-sensitive
aPTT (SHR per 10 seconds increase = 1.10, 1.00–1.21, p =
0.044) were univariably associated with a higher risk of TE
(Table 3). In detail, the 10-year cumulative risk of TE was
60.0% in patients who were diabetic at baseline, as com-
pared to 21.6% in non-diabetic patients (Gray’s test p =
0.002). The 10-year thrombotic risk was estimated at
36.5% in active smokers, as compared to 18.8% in ex- or
never-smokers (p = 0.022). In patients with a lupus-sensi-
tive aPTT > or ≤ the 75th percentile of its distribution
(cut-off at 117.5 s (or for the aPTT ratio at 3.4 multiples
of the median in healthy individuals)), we observed 10-
year thrombotic risks of 43.7% and 17.6%, respectively (p
= 0.004, Additional file 9: Figure S2A–C). A borderline sig-
nificant association was observed between an increased
baseline IgM-isotype aCL antibody level and a higher risk
of TE risk (SHR = 1.30, 95% CI: 0.98–1.74, p = 0.068). Risk
of TE was comparable between patients with established
APS and LA-positive-only patients (SHR = 0.75, 95% CI:
0.36–1.58, p = 0.448), as well as between patients with or
without a prior history of thrombosis (SHR = 0.94, 95% CI:
0.45–1.95, p = 0.865). Oral anticoagulation with a VKA at
baseline was not associated with prospective thrombotic
risk (SHR = 0.93, 95% CI: 0.47–1.86, p = 0.839, Additional
file 10: Figure S3A). Antibodies against domain I of β2-
GPI also did not emerge to be associated with prospective
risk of thrombosis in the univariable analysis (SHR per
1000 CU increase = 0.93, 95% CI: 0.65–1.34, p = 0.711),
and this result prevailed when analyzing the subgroups of
patients (1) with and without a prior history of thrombosis
(p for interaction = 0.323) and (2) younger or older than
50 years at study entry (p for interaction = 0.514). In a
multivariable analysis, we adjusted the results for diabetes,
smoking, and a prolonged lupus-sensitive aPTT ratio
(Table 3, i.e., the variables that were selected below).
The joint multivariable association between diabetes,
smoking, the prolonged lupus-sensitive aPTT ratio
and a higher risk of thrombosis prevailed upon inclu-
sion of all reported variables. This also held true
when adjusting for oral anticoagulation at baseline
(Additional file 11: Table S5). None of the studied
variables was significantly associated with thrombotic
risk after adjusting for these three variables. How-
ever, a weak multivariable association between expos-
ure to statins and a higher risk of thrombosis was
observed. In a sensitivity analysis by event type, dia-
betes and smoking appeared to contribute prognostic
information towards arterial events, and the pro-
longed lupus-sensitive aPTT towards venous events
(Additional file 4: Table S1). Further sensitivity ana-
lyses by event type did not identify signals for associ-
ations between other studied variables and the risk of
arterial and or venous events (not shown).
Thrombosis risk stratification in patients with LA
A backward selection algorithm included diabetes,
smoking, and a prolonged lupus-sensitive aPTT ratio
Table 2 Type of thrombotic event and antithrombotic therapy at the time of event










All TE 32 (100.0%) 14 (45.2%) 4 (12.9%) 7 (22.6%) 8 (25.8%)
Venous TE 16 (50.0%) 8 (53.3%) 3 (20.0%) 3 (20.0%) 3 (20.0%)
Lower extremity DVT 6 (18.8%) 4 (66.7%) 0 (0.0%) 0 (0.0%) 2 (33.3%)
Isolated PE 6 (18.8%) 2 (40.0%) 1 (20.0%) 2 (40.0%) 1 (20.0%)
Lower extremity DVT + PE 1 (3.1%) 1 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Upper extremity DVT 1 (3.1%) 0 (0.0%) 1 (100.0%) 1 (100.0%) 0 (0.0%)
Renal vein thrombosis 1 (3.1%) 0 (0.0%) 1 (100.0%) 0 (0.0%) 0 (0.0%)
Ocular vein thrombosis 1 (3.1%) 1 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Arterial TE 16 (50.0%) 6 (37.5%) 1 (6.3%) 4 (25.0%) 5 (31.3%)
Stroke 8 (25.0%) 3 (37.5%) 0 (0.0%) 1 (12.5%) 3 (37.5%)
TIA 1 (3.1%) 1 (100.0%) 0 (0.0%) 1 (100.0%) 0 (0.0%)
Myocardial infarction 5 (15.6%) 1 (20.0%) 1 (20.0%) 1 (20.0%) 2 (40.0%)
Peripheral artery TE 2 (6.3%) 1 (50.0%) 0 (0.0%) 1 (50.0%) 0 (0.0%)
TE thrombotic events, DVT deep vein thrombosis, PE pulmonary embolism, VKA vitamin K antagonist, LMWH low molecular weight heparin, LDA low dose aspirin,
AC anticoagulation
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Table 3 Baseline predictors of thrombotic risk in patients with LA: univariable and multivariable analyses
Univariable analysis Multivariable analysis
SHR 95% CI p SHR 95% CI p
Demographic characteristics
Age at entry (per 5 years increase) 1.06 0.97-1.17 0.193 1.07 0.99-1.04 0.174
Female gender 0.73 0.34-1.59 0.433 0.92 0.38-2.23 0.859
BMI (per 5 kg/m2 increase) 1.22 0.94-1.58 0.131 1.30 0.94-1.80 0.112
Clinical history
Prior history of thrombosis 0.94 0.45-1.95 0.865 1.40 0.60-3.27 0.436
-Arterial 1.31 0.55-3.12 0.547 1.08 0.42-2.79 0.872
-Venous 0.73 0.37-1.46 0.374 1.06 0.51-2.20 0.870
-Arterial and venous 0.53 0.09-3.23 0.491 0.38 0.04-3.79 0.409
Prior history of pregnancy complicationsa 0.97 0.39-2.40 0.954 0.53 0.19-1.48 0.225
APS 0.75 0.36-1.58 0.448 0.89 0.39-2.00 0.772
Family history of thrombosis 0.70 0.31-1.57 0.390 0.86 0.37-2.00 0.719
Oral anticoagulation at baseline (VKA) 0.93 0.47-1.86 0.839 1.16 0.56-2.39 0.695
Comorbidities
Hypertension 1.28 0.60-2.75 0.525 0.79 0.25-2.53 0.697
Diabetes 5.18 1.87-14.31 0.002 N/A N/A N/A
Statin exposure 2.64 0.71-9.82 0.147 3.34 0.94-11.89 0.063
Autoimmune rheumatic diseasesb 0.81 0.38-1.74 0.594 0.70 0.31-1.60 0.404
Hereditary thrombophiliac 1.22 0.60-2.46 0.586 1.23 0.59-2.55 0.580
Active smoker at baseline 2.11 1.06-4.20 0.034 N/A N/A N/A
Disease-defining autoantibodies
aPTT-LA (per 10-s increase) 1.10 1.00-1.21 0.044 N/A N/A N/A
aPTT ratio (per 1 multiple of the mean) 1.39 1.01-1.93 0.044 N/A N/A N/A
aPTT or aPTT ratio >75th percentiled 2.65 1.32-5.31 0.006 N/A N/A N/A
aβ2-GPI IgM (per 1 logMPL increase) 1.12 0.87-1.46 0.377 1.00 0.75-1.33 0.993
aβ2-GPI IgG (per 1 logGPL increase) 1.03 0.85-1.25 0.778 1.04 0.84-1.28 0.730
aCL IgM (per 1 logMPL increase) 1.30 0.98-1.74 0.068 1.08 0.76-1.53 0.665
aCL IgG (per 1 logGPL increase) 1.10 0.87-1.39 0.436 1.03 0.80-1.33 0.804
LA alone 0.77 0.35-1.71 0.528 0.91 0.41-2.02 0.825
LA + aβ2-GPI 1.33 0.60-2.95 0.476 1.14 0.51-2.53 0.746
LA + aCL 1.42 0.71-2.82 0.323 1.16 0.56-2.42 0.684
Triple positivity (ISTH cut-off)e 1.53 0.77-3.04 0.226 1.22 0.58-2.54 0.598
Triple positivity (Padova cut-off)e 1.37 0.67-2.84 0.390 1.00 0.45-2.23 0.998
Triple positivity (local cut-off)e 1.21 0.59-2.51 0.603 0.91 0.42-1.99 0.812
LA-related autoantibodies
Domain I β2-GPI (per 1000 CU increase) 0.93 0.65-1.34 0.711 0.82 0.43-1.56 0.546
Anti-protein Z IgM (per 10 units increase) 1.00 0.58-1.72 0.999 0.75 0.43-1.30 0.301
Anti-protein Z IgG (per 10 units increase) 1.01 0.74-1.38 0.931 0.90 0.67-1.20 0.457
Antiprothrombin IgM 0.98 0.87-1.10 0.747 0.98 0.94-1.01 0.163
Antiprothrombin IgG 0.99 0.96-1.01 0.373 1.00 0.99-1.00 0.340
Annexin A5 ratio (per 50% increase) 0.83 0.56-1.23 0.347 0.92 0.55-1.53 0.734
Selected laboratory parameters
C-reactive protein (per 5 mg/dL increase) 1.04 0.68-1.57 0.863 0.95 0.63-1.42 0.792
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(binary specification) into a model for thrombotic risk
stratification for patients with LA (Model 1, Table 4).
According to the relative contribution of these variables to
the model, 2 points were assigned for diabetes, and 1
point each for smoking and a prolonged lupus-sensitive
aPTT (Models 2 and 3, further sensitivity analyses for
point assignment are reported in Additional file 12: para-
graph 4). The three-category point-based model (Model 3)
could stratify patients into subgroups with a very low and
very high risk of thrombosis (10-year risk of TE in patients
with 0 (n = 77), 1 (n = 51), or ≥2 (n = 22) points: 9.7%,
30.9%, and 56.8%, respectively; Fig. 1). Internal validation
procedures showed a strong discrimination according to
this point-based rule (Harrell’s C: 0.72), and calibration
was excellent for 10-year thrombotic risk and moderate
for 5-year thrombotic risk (Additional file 13: Figure S4).
Discussion
In this prospective study on patients with persistently
positive LA with or without established APS, we
observed a high incidence of thrombotic complications.
A systematic analysis of risk factors for the occurrence
of thrombosis showed that thrombotic risk was highly
clustered within subjects who had (1) typical cardiovas-
cular risk factors, such as diabetes or active smoking,
and (2) a very prolonged lupus-sensitive aPTT. While
disease-defining autoantibodies such as aCL or aβ2-GPI
were associated with anamnestic thrombotic risk, these
variables appeared to harbor very limited prognostic
information on prospective, long-term thrombotic out-
comes over a median follow-up period of nearly 10 years.
Notably, a simple empirical risk stratification rule
consisting of two clinical and one laboratory variable
Table 3 Baseline predictors of thrombotic risk in patients with LA: univariable and multivariable analyses (Continued)
Triglycerides (per 100 mg/dL increase)f 1.32 0.86-2.01 0.201 1.19 0.96-1.47 0.121
Cholesterol (per 100 mg/dL increase) 1.22 0.58-2.58 0.604 1.31 0.59-2.92 0.513
HDL/LDL ratio (per 1 unit increase) 0.99 0.82-1.20 0.937 1.04 0.89-1.21 0.601
Homocysteine (per 5 μmol/L increase)f 1.25 0.81-1.93 0.316 1.03 0.94-1.12 0.571
Fibrinogen (per 100 mg/dL increase) 1.15 0.80-1.66 0.440 1.23 0.86-1.77 0.253
All presented results are derived from uni- and multivariable Fine and Gray proportional subdistribution hazards regression models (p values ≤ 0.05 are reported in
bold font). In multivariable analysis, estimates are adjusted for the baseline variables diabetes, smoking, and a prolonged lupus-sensitive aPTT ratio
a–fDefined as in the legend of Table 1
fBoth the triglyceride level and the homocysteine level were univariably associated with a higher risk of thrombosis; however, one outlier was present in each of
these variables, and the association between these variables and thrombotic risk disappeared after exclusion of these outliers. The reported subhazard ratios
exclude these outliers
SHR subdistribution hazard ratio, 95%CI 95% confidence interval, p Wald test p value, VKA vitamin K antagonist, N/A not applicable
Table 4 Multivariable models for thrombotic risk in patients with LA
Models SHR 95% CI p Log(SHR) Assigned point
Model 1
Diabetes 3.97 1.29-12.19 0.016 1.38 2
Active smoking 2.42 1.15-5.06 0.019 0.88 1
Prolonged aPTT-LA ratioa 2.28 1.04-4.99 0.039 0.82 1
Model 2
0 point (n = 77 (51.3%)) Ref. Ref. Ref. - -
1 point (n = 51 (34.0%)) 2.84 1.14-7.02 0.024 - -
2 points (n = 15 (10.0%)) 8.56 2.91-25.17 <0.0001 - -
3 points (n = 7 (4.7%)) 8.45 2.21-32.35 0.002 - -
Model 3
0 point (n = 77 (51.3%)) Ref. Ref. Ref. - -
1 point (n = 51 (34.0%)) 2.84 1.14-7.02 0.024 - -
≥ 2 points (n = 22 (14.7%)) 8.53 3.19-22.78 <0.0001 - -
Model 1 is a multivariable model including the three variables as binary specifications (a prolonged lupus-sensitive aPTT was defined as being above the 75th
percentile (Q3) of this variable’s distribution (cut-off: 117.5 s)). Model 2 is a multivariable model based on the points that were assigned for the relative
contribution of the individual variables (as represented by the log (subdistribution hazard ratios) in Model 1). In Model 3, the two highest risk categories were
combined in a post hoc fashion, because the coefficients showed a similar relative risk for 2 and 3 points. Model 3 is the final product of our prediction
model-building strategy, and observed risks according to this point-based rule are shown in Fig. 1
SHR subdistribution hazard ratio, 95%CI 95% confidence interval, p Wald test p value, log(SHR) natural logarithm of the SHR, Ref reference category
aProlonged aPTT ratio defined by a prolongation above the 75th percentile of this variable’s distribution (this corresponds to cut-off at 117.5 s (or for the aPTT
ratio at 3.4 multiples of the median in healthy individuals))
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allowed us to stratify our patients into subgroups with a
very high and very low risk of thrombosis.
Two-thirds of the LA-positive patients in this study
had a history of at least one thrombotic event, and ven-
ous events were the predominant anamnestic event type.
Two-thirds of the patients with a history of thrombosis
were on oral anticoagulants at baseline, which reflects
the decision of individual physicians to anticoagulate
these patients due to a high perceived risk of recurrent
thrombosis. In the baseline analysis, we found univari-
able associations between some aPL-associated
autoantibodies and the anamnestic risk of thrombosis.
Specifically, we could observe that the presence of anti-
bodies against domain I of β2-GPI and “triple positivity”
were more frequent in patients who had a history of
thrombosis. These results confirm and validate several
previous reports that have implicated these antibodies in
the pathogenesis of APS [9, 10, 12, 13, 29, 30], but they
also add to the growing body of evidence that shows
inconsistent associations between aPL-associated auto-
antibodies and anamnestic thrombotic risk [3, 16].
Among non-canonical aPL-associated antibodies [11],
such as antibodies against protein Z or prothrombin, we
only observed a weak association between higher IgM-i-
sotype antibodies against protein Z and a higher risk of
anamnestic thrombosis. Collectively, these findings do
not support the concept that antibodies against protein
Z or prothrombin correctly identify LA positive patients
with a history of thrombosis.
After a median follow-up interval of nearly 10 years
and more than 1000 person-years spent at risk of throm-
bosis and death, we observed a high incidence of throm-
botic complications despite the fact that the majority of
patients with a history of thrombosis were on anticoagu-
lation therapy. Importantly, approximately three out of
four thrombotic events occurred while patients were
receiving antithrombotic medication with VKA, LMWH,
and/or LDA, suggesting that episodes of hypercoagula-
bility in LA-positive patients can induce overt
thrombosis despite antithrombotic therapy. The 10-year
cumulative TE incidence of 24.3% compares well to the
thrombotic risk observed in the WAPS study [31] and
the very large Euro-Phospholipid Project registry [6], but
was lower than the value in the recently published
Piedmont cohort study [32] and higher than that in the
recently published study by Pengo et al. [30]. Further,
the relative frequencies of arterial and venous events as
well as the proportion of patients receiving anticoagula-
tion while developing an event were very similar to the
results of the Euro-Phospholipid study [6].
In our study, we were surprised to observe that none
of the studied aPL-associated autoantibodies were con-
sistently associated with the risk of developing throm-
bosis. This held true also for “triple positivity.” While
Fig. 1 Cumulative incidence of thrombotic risk according to the proposed empirical risk stratification rule. 1 point is assigned for either the
baseline presence of active smoking or a prolonged lupus-sensitive aPTT ratio, and 2 points are assigned for the baseline presence of diabetes.
TE thromboembolic events
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triple positivity has been shown to be a significant
thrombotic risk factor in the WAPS study [7], several
more recent prospective cohorts have also observed a
lack of association between triple positivity or other LA-
related autoantibodies and thrombosis [30, 32, 33].
Among the studied antibodies, IgG-isotype antibodies
against domain 1 of β2-GPI showed the strongest and
most consistent associations with both anamnestic risk
of thrombosis and pregnancy complications. However,
also with this specific antibody we did not observe an
association with prospective thrombotic risk in the over-
all cohort or when performing subgroup analyses in
patients with and without a prior history of thrombosis.
One reason for the absence of an association between
LA-related autoantibodies and prospective thrombotic
risk in our cohort could be that our study population
was highly enriched with “high-risk” LA-positive
patients, as this was our inclusion criteria and as LA is
known to be the strongest laboratory predictor of
thrombosis to date in APS patients [3, 29]. However,
considering the accumulating prospective evidence
about a lack of association between these antibodies and
prospective thrombotic risk [3], our results support the
suggestion that LA-related autoantibodies may be much
more relevant for making the diagnosis of APS, rather
than for making a prognostic statement about future
thrombotic risk in these patients.
Interestingly, we found very strong associations
between the presence of typical cardiovascular risk fac-
tors at baseline, such as diabetes and smoking, with an
excessively increased risk of thrombosis in our cohort.
Further, we have observed a weak association between
exposure to statins and a higher risk of thrombosis. This
is consistent with the recently published results from the
Piedmont cohort study, which found a tenfold increased
thrombotic risk in LA patients with diabetes [32]. Fur-
ther, a risk score for anamnestic thrombotic risk in pa-
tients with SLE, the Global Anti-Phospholipid Syndrome
Score (GAPSS), includes two general cardiovascular risk
factors: hypertension and hyperlipidemia [34]. Both
hypertension and dyslipidemia were strongly correlated
with diabetes in our study. We can derive two hypoth-
eses from these findings. First, diabetes and smoking are
modifiable risk factors. Although prospective clinical
trial data are absent, we can speculate that smoking ces-
sation efforts and interventions to control blood glucose
levels and improve metabolic function may reduce the
risk of TE in LA-positive patients. Second, preclinical
evidence from animal models has demonstrated that the
presence of LA-related autoantibodies alone is insuffi-
cient for causing overt thrombosis, and a “second hit”
such as inflammation or infection may be necessary to
transform the prothrombotic potential induced by LA-
related autoantibodies into overt thrombosis [35]. Our
data support the concept that diabetes and active smok-
ing may represent two factors for this “second-hit
phenomenon” and that the adverse cardiovascular con-
sequences of diabetes and smoking may lead to a dele-
terious thrombotic risk increase in patients with LA.
Interestingly, a prolongation of a lupus-sensitive aPTT
(PTT-LA, Diagnostica Stago, Asniere-sur-Seine, France),
which is used as a screening tool for making the diagnosis
of LA at our center, was also strongly associated with a
higher prospective TE risk, and this association prevailed
after controlling for oral anticoagulation and other risk
factors including diabetes and smoking. We hypothesize
that the association between this laboratory variable and
thrombosis risk is likely not causal. Rather, a prolonged
lupus-sensitive aPTT may represent a proxy variable for a
more aggressive disease phenotype, leading to a stronger
polyclonal autoantibody production and thus a stronger in
vitro inhibition of the coagulation cascade. This hypoth-
esis is supported by previous case-control studies that
have implicated the length of a lupus-sensitive aPTT with
thrombosis in LA [13, 36, 37].
In a sensitivity analysis estimating the risk of arterial
and venous prospective events separately, we could
observe that diabetes and smoking appeared to be more
relevant for predicting arterial events, whereas the pro-
longed lupus-sensitive aPTT was more associated with
the occurrence of venous events. Although this analysis
has very low power, it illustrates a differential pathobiol-
ogy of these three risk factors.
Based on our univariable findings and a prespecified
model-building algorithm, we identified a simple empir-
ical risk stratification rule including the variables
diabetes, smoking, and a prolonged lupus-sensitive
aPTT ratio which could discriminate our patients into
subgroups with a very high and very low risk of throm-
bosis. Internal validation procedures showed that this
risk stratification rule featured a high discriminative per-
formance and was well calibrated for prediction of 10-
year thrombotic risk. Some miscalibration was observed
for 1- and 5-year thrombotic risk prediction in patients
with 1 or ≥2 points, where the rule somewhat over- and
underpredicted the observed thrombotic risk. While this
rule still has to be validated in an external cohort, its
most promising feature is that it could identify a very
large subgroup of patients representing 50% of our
patient population who had a very low risk of throm-
bosis with the current management strategy, namely
treating patients with a history of thrombosis with
oral anticoagulation. Clinically, an intensification of
antithrombotic therapy will likely have a poor benefit-
risk ratio in this large subgroup. Conversely, we iden-
tified a smaller subgroup representing about 15% of
our population who experienced an excessive throm-
botic risk.
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Limitations and future research
Although this study represents one of the very few pro-
spectively executed studies with stringent inclusion cri-
teria in the field of APS research, several limitations have
to be mentioned. First, this study includes patients who
tested repeatedly positive for LA with and without a his-
tory of thrombosis and included subgroups of patients
with other potentially relevant factors, such as concomi-
tant autoimmune rheumatic diseases. Consequently, our
results are not directly generalizable to other patient
groups included in the wide and heterogenic spectrum of
APS, such as patients with SLE [34, 38] or patients who
are positive for aCL or aβ2-GPI but not LA [39]. Second,
our present analysis cannot provide a valid estimate for
the potential benefit of anticoagulation in LA-positive pa-
tients. In this observational study, patients who were
anticoagulated at baseline had a similar risk of prospective
thrombosis as patients who were not anticoagulated. Of
course, this must not be interpreted as an absence of effi-
cacy, because reverse causality has likely confounded this
observational result. Indeed, patients with a history of
thrombosis had a substantially higher probability of being
on oral anticoagulation, so anticoagulation may rather re-
flect the decision of individual physicians to anticoagulate
those patients with the highest perceived risk of throm-
bosis. Other prospective investigators in the field have also
faced this problem [32]. Third, because prospective data
in LA-positive patients are scarce, we could not yet valid-
ate our empirical risk stratification rule in an external co-
hort. Fourth, our suggested risk stratification rule has
some loss of information as compared to the full multivar-
iable model, which is attributable to “rounding” of regres-
sion coefficients to a point-based system. In detail, the
relative contribution of diabetes towards thrombotic risk,
as compared to smoking status and the lupus-sensitive
aPTT, would have led to an uneven point score of 1.6 for
diabetes, which was rounded to 2. Nevertheless, we would
like to mention that our cohort features several strengths,
including a stringent prospective design with a long
follow-up, a small drop-out rate, and the time-dependent
censoring of patients who became LA negative over time.
Conclusions
We conclude that established risk factors for vascular
events in the general population also turned out to be
relevant in patients with LA. This is consistent with the
hypothesis that these risk factors represent the necessary
“second hit” for eliciting thrombosis in patients with LA.
Moreover, a very long lupus-sensitive aPTT was predict-
ive for the occurrence of TE in these patients as well.
These associations were independent of anticoagulation.
Disease-defining antibodies, such as those against cardi-
olipin or β2-GPI (including those against domain I),
showed a strong association with anamnestic risk of
thrombosis; however, they did not predict the future oc-
currence of TE in this LA-positive patient population. In
conclusion, our results suggest that, above standard
anticoagulation, interventions to control and improve
metabolic status and smoking habits might influence the
rates of future TE in patients with known persistent LA.
A simple empirical risk stratification rule can identify a
very large subgroup of LA-positive patients with a very
low prospective risk of thrombosis.
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